Overview

Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Status:
Completed

Trial end date:
2006-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with simvastatin 40 mg in patients with low HDL

Phase:

Phase 2

Details

Lead Sponsor:

Akros Pharma Inc.

Treatments:

Dalcetrapib
Simvastatin